Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
| 대상 질환 | Glioblastoma |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | University of Pennsylvania |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 39 명 |
| 중재(약물) | INCMGA00012, INCAGN01876, SRS, Brain surgery |
| 시작일 | 2020년 6월 23일 |
| 완료일 | 2022년 9월 8일 |
| 결과 공개일 | 2023년 9월 15일 |
요약
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.
Objective Radiographic Response (ORR)
| GITR + PD1, SRS (Cohort A) | 0 % of participants with response |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen